Search Results for: About
2022 Supplement Consumer Survey validates K2 sales growth, identifying younger demographics seeking core benefits and focusing on branded ingredients. MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (XX July 2022) – The Industry Transparency Center announced a new survey of 3,500 dietary supplement consumers. The “ITC Insights – 2022 Supplement Consumer Survey” was conducted … Continue reading VITAMIN K2 USE, AWARENESS CONTINUES TO GROW: NEW CONSUMER SURVEY
2022 Supplement Consumer Survey validates K2 sales growth, identifying younger demographics seeking core benefits and focusing on branded ingredients.
MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (XX July 2022) – The Industry Transparency Center announced a new survey of 3,500 dietary supplement consumers. The “ITC Insights – 2022 Supplement Consumer Survey” was conducted by Dynata from March 1-26, 2022, and was written and analyzed by the Industry Transparency Center. The breakdown of supplement consumers included 1,000 from the US, 1,000 from China, 500 from the UK, 500 from Germany, and 500 from Italy. Participants identifying as Female represented 52% of respondents, and Men represented 48% of respondents. Ages ranged from 18 to 65+ years.
Key Findings from the Survey:
- 63% reported, “I am proactive about my health and take steps to lower health risks,” while 76% said, “I use/have used vitamins, minerals, herbs or other dietary supplements to help manage my health.”
- 62% reported using Vitamin K2 supplements, ranking in the top 10 ingredients used.
- The 18 – 54 age group brackets showed an increase in usage of Vitamin K2 compared to those 55+.
- No single supplement increased usage across every country; however, Vitamin K2 was one of the closest to achieving universal growth. K2 also saw a sharp increase in use from 2020-2022.
- “Perceived effectiveness” of K2 was greater in total supplement users surveyed compared to “regular users.” This suggests to the researchers that future growth is likely as people who do not currently use Vitamin K2 regularly have a high perception of it.
- For supplement users of branded ingredients, “Quality,” “Safety,” “Trust,” “Efficacy,” and “Clinical Validation” ranked as the top 5 reasons for use.
- Bone Health and Heart Health ranked as the top reasons for using Vitamin K2, especially for regular users. While irregular users noted various reasons, including “bioavailability of other supplements.”
- Brain Health and Mental Acuity also ranked relatively high and have a low gap between irregular and regular users. Researchers believe this partially confirms “the earlier hypothesis of potential opportunities in this area.”
“This survey confirms what we see commercially in many ways. Consumers have a high trust and interest in Vitamin K2, especially those looking for specific health benefits,” according to Xavier Berger, Global Market Manager with Gnosis by Lesaffre. “It is also nice to see that ‘quality,’ ‘efficacy’ (i.e., proof that it works), and ‘safety’ are recognized in the branded ingredients. MenaQ7 is a standout Vitamin K2 in this regard, as it is the only K2 as MK-7 with clinical validation confirming bone and cardiovascular benefits.”
Interestingly, 37% of regular users responded that they always look for branded ingredients and are willing to pay a premium, with an additional 22% looking for them but not willing to pay a premium. While nearly 60% of Vitamin K2 users are looking for branded ingredients, products utilizing these premium materials represent a competitive edge.
Berger added, “Very interesting is that 67% of consumers said they look for a specific Vitamin K2 brand while purchasing their supplements, and our two brands – MenaQ7 K2 as MK-7 and vitaMK7 – are in the top 3 brands most sought out.”
The General Criteria for Participation included Supplement users and qualification questions that corrected for participants who proclaimed they were ‘not a user’ in questioning.
# # #
About the Industry Transparency Center
The Industry Transparency Center (ITC) is a strategy and insights firm driving transparency in the health ingredients and natural products industries through four key pillars: Insights, Stewardship, Strategy, and Community. ITC provides guidance to organizations across the globe via strategic insights, category stewardship, world-class events and thought leadership. ITC also operates the Global Prebiotic Association, Global Curcumin Association, Collagen Stewardship Alliance and Coconut Coalition of the Americas. Learn more at ITCStrategy.com
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and application capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220
IECN 2022 poster presentation highlights the non-canonical role of MenaQ7® Vitamin K2 on vascular calcification, widening cardio evidence and potential sports applications. MARCQ-EN-BAROEUL, FRANCE AND EAST BRUNSWICK, NJ (29 MAR 2022) – A poster presented 25 March 2022 at the 2nd International Electronic Conference on Nutrients (IECN) detailed recent research showing that … Continue reading Vitamin K2 Impact on Oxidative Stress, ATP Production: New Evidence
IECN 2022 poster presentation highlights the non-canonical role of MenaQ7® Vitamin K2 on vascular calcification, widening cardio evidence and potential sports applications.
MARCQ-EN-BAROEUL, FRANCE AND EAST BRUNSWICK, NJ (29 MAR 2022) – A poster presented 25 March 2022 at the 2nd International Electronic Conference on Nutrients (IECN) detailed recent research showing that MenaQ7® Vitamin K2 as MK-7 countered induced oxidative stress in vascular smooth muscle cells, ultimately lowering oxidative stress while increasing ATP production. The global event focuses on nutrition support for immunity and countermeasure effects on infection, inflammation, and oxidative stress.
The poster, “Non-Canonical Role of MK-7 in Vascular Smooth Muscle Cells” [1], was presented to the prestigious audience by PhD student Asim Cengiz Akbulut, Department of Biochemistry, CARIM, Maastricht University, with the support of his supervisor and senior author on the abstract Prof. Leon Schurgers, Professor of Biochemistry of Vascular Calcification and Vice-Chair of Biochemistry at CARIM, Maastricht University. Akbulut shared recent findings from a cellular study where the vitamin K pathway was antagonized by warfarin, inducing oxidative stress in vascular smooth muscle cells (SMCs), contributing to pathological phenotype perpetuating vascular calcification and cardiovascular disease.
After introducing Vitamin K2 as MK-7 (as MenaQ7®), measurements were taken of ATP, oxidative stress, extracellular vesicles (EV). Key findings include: interference with vitamin K metabolism by warfarin results in increased intracellular oxidative stress and EV secretion, MK7 counteracts intracellular oxidative stress, both under normal conditions and warfarin-induced, and MK7 increases ATP (adenosine triphosphate) production, even in the presence of warfarin.
The authors concluded: “Our experiments show that in primary human SMCs, MK-7 lowers oxidative stress and EV release and increases ATP production. This pathway points to a non-canonical role of MK-7 in the prevention of vascular calcification, unrelated to its canonical role as cofactor for the posttranslational modification of MGP.”
Since 2004, NattoPharma (now Gnosis by Lesaffre) has worked closely with the Maastricht University in documenting the benefits of the company’s exclusive vitamin K2 as MK-7 brand MenaQ7®. These new findings are in line with previous research eliminating that vitamin K2 decreases oxidative stress[2], as well as the non-canonical role of K2 inhibiting inflammatory markers[3].
“We are incredibly encouraged by the results of this study highlighting the potential of Vitamin K2 as MK-7 for healthy aging, as oxidative stress is involved in several age-related conditions, such as increased cardiovascular risk, chronic kidney conditions, and neurodegenerative disorders,” explains Hogne Vik, Gnosis by Lesaffre Chief Medical Officer. “This contributes nicely to our already substantial body of research showing MenaQ7 is a cardio-protective nutrient and reaffirms why the medical community is interested in the ongoing study of this important nutrient for the betterment of global health.
“Further, evidence showing MenaQ7 increased the production of ATP shines highlights K2 as MK-7 as a potentially essential nutrient for sports nutrition,” concludes Vik. “While it is preliminary data, we are excited about the next steps of this important research to validate the additional health benefits and applications.”
# # #
References:
1 https://sciforum.net/paper/view/12401
2 https://www.atherosclerosis-journal.com/article/S0021-9150(19)31253-5/fulltext
3 https://pubmed.ncbi.nlm.nih.gov/27200471/
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and applications capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220
New evidence draws an association between Vitamin K insufficiency and cognitive dysfunction, further argument for the potential of Vitamin K2. MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (26 APRIL 2022) – Frontiers in Nutrition published a new large-population cross-sectional study that demonstrated the association of vitamin K insufficiency with cognitive function. In … Continue reading VIT K INSUFFICIENCY LINKED TO BRAIN HEALTH: NEW PAPER
New evidence draws an association between Vitamin K insufficiency and cognitive dysfunction, further argument for the potential of Vitamin K2.
MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (26 APRIL 2022) – Frontiers in Nutrition published a new large-population cross-sectional study that demonstrated the association of vitamin K insufficiency with cognitive function.
In the study, “Association of Vitamin K Insufficiency with Cognitive Dysfunction in Community-Dwelling Older Adults”[1], Japanese researchers enrolled a total of 800 community-dwelling older adults (mean age = 75.9) and conducted a geriatric health examination, including a Mini-Mental State Examination (MMSE) and a blood test. Examining the concentration of undercarboxylated osteocalcin (ucOC) in serum, which is a biomarker for vitamin K insufficiency, they demonstrated the association of the concentration of undercarboxylated osteocalcin (ucOC) in serum, which is a biomarker for vitamin K insufficiency, with cognitive function. By using binary logistic regression analysis, the risk of cognitive impairment equivalent or below the mild cognitive impairment level for each tertile of ucOC was examined, with the lowest tertile as the reference.
The results showed a significant association of impaired cognitive function and concentration of ucOC in the highest tertile of ucOC, with the odds ratio of 1.65 (95% CI, 1.06 to 2.59, P = 0.028). When the analysis was repeated with each domain of MMSE score*, the highest tertile of ucOC was associated with impaired orientation, calculation, and language.
The finding of the present study was in line with the previous epidemiological studies, showing that lower vitamin K intake is associated with cognitive impairment. The researchers reported, “As far as we know, this is the first report on the significant association of single ucOC measurement and cognitive impairment. Our analysis also suggests that vitamin K insufficiency could be associated with selected categories of cognitive function. Since the single measurement of ucOC in serum is a simple and widely available method for vitamin K evaluation, it could be useful as a biomarker of neurodegenerative diseases affecting the cognitive functions.”
These results are supported by another recently published paper from Spain[2] that assessed two years of changes in dietary K intake with cognitive function measured through neuropsychological performance tests. The researchers concluded that “An increase of the intake of dietary vitamin K was associated with better cognitive function scores, independently of recognized risk factors for cognitive decline, in an older adult Mediterranean population with high cardiovascular risk.”
While the Japanese study examined “vitamin K,” there are several studies that showed that MenaQ7® Vitamin K2 as MK-7 improved K status as measured by ucOC, and these were done in healthy adult and child populations.[3,4]
“We have worked with world-renowned researchers – as NattoPharma and that work continues at Gnosis by Lesaffre – to confirm the safe and effective health benefits of MenaQ7 Vitamin K2 as MK-7. Elucidating the important mechanism of activating K-dependent proteins, including osteocalcin and Matrix Gla protein (MGP), was a foundational piece of that work,” explains Dr. Hogne Vik, chief medical officer with Gnosis by Lesaffre, who referenced an important 2021 US-based review paper highlighting Vitamin K2 as a potential strategy for Alzheimer’s disease.[5] “Based on our research and the critical work that continues, we can hypothesize that K2 supplementation could prove beneficial in the brain development of children and support healthy brain function in adults.”
Dr. Vik also noted that while Vitamin K2 as MK-4 has been noted as the main form of vitamin K in the brain, “it is important to mention that in-vivo research supports that supplementation with K2 as MK-7 increases MK-4 content in the brain tissue,” he concluded.
# # #
References:
1 Azuma K et al. Association of Vitamin K Insufficiency With Cognitive Dysfunction in Community-Dwelling Older Adults. Front. Nutr. (2022) 8:811831. doi: 10.3389/fnut.2021.811831
2 Camacho-Barcia L et al. Vitamin K dietary intake is associated with cognitive function in an older adult
Mediterranean population. Age Ageing. 2022 Feb 2;51(2):afab246. Doi: 10.1093/ageing/afab246.
3 Knapen MHJ et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013 Sep;24(9):2499-507. doi: 10.1007/s00198-013-2325-6. Epub 2013 Mar 23. PMID: 23525894.
4 Theuwissen E et al. Vitamin K status in healthy volunteers. Food Funct. 2014 Feb;5(2):229-34. doi: 10.1039/c3fo60464k. PMID: 24296867.
5 Popescu A and German M. “Vitamin K2 Holds Promise for Alzheimer’s Prevention and Treatment.” Nutrients. 2021,13,2206.
* Explanation of MMSE: The maximum MMSE score is 30 points. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia. On average, the MMSE score of a person with Alzheimer’s declines about 2 to 4 points each year.
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and applications capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220
PhD candidate supported by a research grant awarded to NattoPharma (now Gnosis by Lesaffre) attains his degree, continues to build evidence of K2 cardiovascular and bone benefits. MARCQ-EN-BAROEUL, FRANCE AND EAST BRUNSWICK, NJ (10 MAR 2022) – PhD candidate Grzegorz Wasilewski defended his thesis on February 22, 2022, at Maastricht University, Cardiovascular Research … Continue reading Researcher Defends Vitamin K2 Doctoral Thesis
PhD candidate supported by a research grant awarded to NattoPharma (now Gnosis by Lesaffre) attains his degree, continues to build evidence of K2 cardiovascular and bone benefits.
MARCQ-EN-BAROEUL, FRANCE AND EAST BRUNSWICK, NJ (10 MAR 2022) – PhD candidate Grzegorz Wasilewski defended his thesis on February 22, 2022, at Maastricht University, Cardiovascular Research Institute Maastricht (CARIM), The Netherlands. His work was supported by funding from the Norwegian Research Council and a research grant awarded to NattoPharma ASA (now Gnosis by Lesaffre).
The thesis, “Calcium Paradox – the role of vitamin K in the bone-vascular axis”1, highlighted the published work Wasilewski has done in conjunction with and under the leadership of Prof. Leon Schurgers, Professor of Biochemistry of Vascular Calcification and Vice-Chair of Biochemistry at CARIM, Maastricht University. This research includes an important review paper2, an in-vivo study exploring the combination of phosphate binder therapy with vitamin K2 to inhibit vascular calcification in kidney patients3, and an in-vitro study examining the impact of K2 as MK-7 supplementation in osteogenesis4.
“Scientists from Maastricht University have recently shown that combining vitamin K2 with phosphate binder treatment reduces vasculature and cartilage calcification. Additionally, they also discovered a novel role of vitamin K2 in beneficially affecting osteoblast maturation from induced pluripotent stem cells. Their findings might be clinically relevant for chronic kidney disease patients and for those seeking stem-cell therapies,” Wasilwski said in his defense.
“With these discoveries, we are a step closer towards management of vascular calcification in chronic kidney disease patients. Using our novel experimental animal model of chronic kidney disease and vitamin K-deficiency demonstrates the beneficial role of combining phosphate binders with vitamin K2 in reducing vascular calcification compared to phosphate binders alone,” he added, noting that future clinical trials are needed to address whether vitamin K2 needs to be implemented in standard treatment therapy with phosphate binders. “Further, we have discovered a novel non-canonical role of vitamin K2 in aiding collagen synthesis in our iPSC model of osteoblast differentiation. Our results are fascinating as it changes the perspective on how MK-7 can impact skeletal disorders as well as paving the way for stem cell-based personalized therapy.”
Since 2004, NattoPharma has worked closely with the Maastricht University in documenting benefits of the company’s exclusive vitamin K2 as MK-7 brand MenaQ7®. The research grant awarded to the NattoPharma International Research Network provided training in innovative therapeutic strategies that include MenaQ7, integrating early detection and prevention, to yield novel approaches to the management of chronic vascular and metabolic diseases that affect the increasing aging population of Western societies.
Wasilewski was under the supervision of Prof. Leon Schurgers, a co-leader in the multidisciplinary research project together with Dr. Hogne Vik, Chief Medical officer at NattoPharma (now Gnosis by Lesaffre). This project is emblematic of NattoPharma’s continuation of the multi-year vitamin K2 research partnership with CARIM (as announced in 2020), to which Gnosis by Lesaffre has committed.
“We are honored to have had the opportunity to support this distinguished researcher, and to see him come through this program making a substantial contribution to the argument that Vitamin K2 as MK-7 can indeed change the face of global health,” says Dr. Vik. “This work is so important as we continue to build an unshakeable science-based argument for Vitamin K2 as MK-7 is an essential nutrient worthy of its own Recommended Daily Intake (RDI), but also as a potential therapy for patient populations who express excessive calcification as a symptom of their condition.”
# # #
References:
2 https://pubmed.ncbi.nlm.nih.gov/30805347/
3 https://pubmed.ncbi.nlm.nih.gov/34718756/
4 https://pubmed.ncbi.nlm.nih.gov/33585456/
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and applications capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220
Literature review documents safe use and important health effects of vitamin K2 in child populations, noting consideration for pregnant and nursing women. MARCQ-EN-BAROEUL, FRANCE AND EAST BRUNSWICK, NJ (12 JANUARY 2022) – Children has published an important review paper that documents vitamin K2’s role in various physiological processes, its safe history of use, … Continue reading Vit K2 Impacts Children’s Health, Disease: New Review
Literature review documents safe use and important health effects of vitamin K2 in child populations, noting consideration for pregnant and nursing women.
MARCQ-EN-BAROEUL, FRANCE AND EAST BRUNSWICK, NJ (12 JANUARY 2022) – Children has published an important review paper that documents vitamin K2’s role in various physiological processes, its safe history of use, and that children express the greatest need for K2 supplementation.
The paper, “The Impact of Vitamin K2 (Menaquinones) in Children’s Health and Disease: A Review of the Literature “1, presents a thoughtful organization of data highlighting the differences between vitamins K1 and K2, as well as K2 as menaquinone-4 (MK-4) and as MK-7; factors contributing to the prevalence of K deficiency; and how child populations can benefit from correcting this deficiency, according to Dr. Katarzyna Maresz, president of the International Science and Health Foundation, and co-author to this paper.
“Vitamin K2 activates K-dependent proteins that support many biological functions, including bone mineralization, the inhibition of vascular stiffness, the improvement of endothelial function, the maintenance of strong teeth, brain development, joint health, and optimal body weight,” Dr. Maresz explains. “Due to the transformation of food habits in developed countries over the last five decades, vitamin K and, specifically, vitamin K2 intakes among parents and their offspring have decreased significantly, resulting in serious health implications. The therapeutics used in pediatric practice (antibiotics and glucocorticoids) are also to blame for this situation.”
Dr. Maresz teamed with a nutritionist colleague at Jagiellonian University Medical College to complete the review, in which they discuss K2 as MK-7 supplementation is worth considering for expectant mothers as a means of setting their children on the best path to health. “The lack of adverse effects of MK-7 makes it the ideal choice for supplementation by pregnant and nursing women and children, both healthy and suffering from various malabsorptions and health disorders, such as dyslipidemia, diabetes, thalassemia major (TM), cystic fibrosis (CF), inflammatory bowel diseases (IBD), and chronic liver diseases,” the authors write.
“As we continue our pursuit of a K2-specific Recommended Daily Intake (RDI), this review serves as a substantial argument,” says Dr. Hogne Vik, Chief Medical Officer with Gnosis by Lesaffre. “Particularly as it illustrates the overwhelming impact K2 deficiency has on child populations, and it illustrates how parents’ deficiencies feed into the state of their children’s health. We have stressed for more than a decade the impact that Vitamin K2 can have on children’s health. As thrilling as it was to see the first child-specific formulas featuring MenaQ7 K2 hit the market a few years ago, we have so much more to do to improve the health of our children.”
# # #
Reference:
1 Kozioł-Kozakowska, A.; Maresz, K. The Impact of Vitamin K2 (Menaquionones) in Children’s Health and Diseases: A Review of the Literature. Children 2022, 9, 78. https://doi.org/10.3390/children9010078
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and applications capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220
One of the most-recognized and sought-after certifications is « Non-GMO Project Verified ». The good news: If your supplement product features MenaQ7 K2, you have always met this need. Consumers have been asking for Non-GMO transparency for more than two decades. A 2020 survey of 2000 individuals in the US and Canada shows that “USDA Organic” and … Continue reading MenaQ7 K2 Non-GMO Verified … Always
One of the most-recognized and sought-after certifications is « Non-GMO Project Verified ». The good news: If your supplement product features MenaQ7 K2, you have always met this need.
Consumers have been asking for Non-GMO transparency for more than two decades. A 2020 survey of 2000 individuals in the US and Canada shows that “USDA Organic” and “Non-GMO Project Verified” are the most recognizable and sought-after certifications on food products. Further, it has now become all but mandatory in the natural product industry especially as brands prepare to comply with new laws and store policies.
The good news: If your dietary supplement product features MenaQ7 Vitamin K2 as MK-7, you have always been compliant. If your K2 product has not included MenaQ7, you may want to reconsider your supplier.
Pioneering the K2 Category
While many suppliers are entering the market offering Vitamin K2, MenaQ7 Vitamin K2 as MK-7 started the category when it was first introduced 15 years ago. All the science confirming safe and efficacious bone and heart health benefits used MenaQ7 as the actual source material. Those studies – 22+ to date with more currently underway – were conducted in healthy and patient populations, adults as well as children.
But being a pioneer is not just about driving the clinical evidence; it also meant that MenaQ7 be held to the highest standards, including achieving Non-GMO Verification from the Non-GMO Project, a non-profit 501(c)3 organization that offers North America’s only third-party verification and labeling for non-GMO (genetically modified organism) food and products. The complete MenaQ7 line was verified 8 years ago, while the following certifications were also obtained:
• Novel Food Status
• Self-Affirmed GRAS
• Halal
• Kosher
• Suitable for Vegans
• Allergen-free
• Free from Pesticides and Toxins
What Does This Mean For Brand Owners?
Companies that seek to invest to offer the highest quality products must insist their raw material suppliers support their efforts. This means not only ensuring their ingredients are clinically validated, but that they achieve the certifications that will allow finished products to stand out on crowded shelves.
Remember that 2020 consumer survey? Among the 15 certification marks that appear on food products, 63% of consumers recognize USDA Organic and 54% recognize the Non-GMO Project butterfly logo. The next most recognized certification was Gluten-Free (32%) and then Fair Trade (30%).
Choosing MenaQ7 Vitamin K2 as MK-7 means you are one step closer to being able to label your finished product as “Non-GMO,” earning an important and growing faction of consumers’ purchases.